Funda Meric‐Bernstam

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

14.9Author DataRank

Indexed papers

16in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 16 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Papers

Driven by 123 papers — median percentile 0. Top paper: “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics”.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cell(2018)10.1016/j.cell.2018.03.033

Top 3%

6.4DataRank

Top 3%447 citations

Matthew H. Bailey, Hoifung Poon, Vesteinn Thorsson, Antonio Colaprico, Andreas Bender +883 more

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

Cell Reports(2018)10.1016/j.celrep.2018.03.046

N/A

5.5DataRank · unranked

186 citations

Francisco Sanchez-Vega, Konnor C. La, Joshua Armenia, Walid K. Chatila, Augustin Luna +869 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0450

N/A

3.0DataRank · unranked

101 citations

John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney +9 more

Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1209

N/A

2.3DataRank · unranked

51 citations

Qin Zhou, Bastien Nguyen, Celeste Yu, Eva M. Lepisto, Mónica Arnedos +27 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Breast Cancer Research(2021)10.1186/s13058-021-01406-x

N/A

1.8DataRank · unranked

70 citations

Ming Zhao, Erkan Yuca, Allen Annis, Kurt W. Evans, David Sutton +13 more

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00251-7

N/A

1.4DataRank · unranked

36 citations

Gerald Batist, Funda Meric‐Bernstam, Peter Kabos, Iben Spanggaard, Aňa Lluch +22 more

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004822

N/A

1.4DataRank · unranked

44 citations

Bettzy Stephen, Daniel D. Karp, Sarina A. Piha‐Paul, David S. Hong, D Jain +10 more

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

The Oncologist(2021)10.1002/onco.13682

N/A

1.4DataRank · unranked

47 citations

Henry Hiep Vo, Vivek Subbiah, Filip Jankú, Sarina A. Piha‐Paul, Bülent Yılmaz +7 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215

N/A

1.3DataRank · unranked

41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Cell(2018)10.1016/j.cell.2018.03.035

N/A

1.2DataRank · unranked

3322 citations

Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La +891 more

Clonal evolution in breast cancer revealed by single nucleus genome sequencing

Nature(2014)10.1038/nature13600

N/A

1.1DataRank · unranked

1101 citations

Jill Waters, Marco L. Leung, Anna Unruh, Whijae Roh, Xiuqing Shi +14 more

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

Journal of Hepatology(2023)10.1016/j.jhep.2023.10.041

N/A

1.0DataRank · unranked

36 citations

Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott +12 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Annals of Oncology(2020)10.1016/j.annonc.2020.10.599

N/A

0.829DataRank · unranked

251 citations

Tao Shen, S. Terzyan, X. Liu, Xueqing Hu, Khadijah Patel +8 more

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Nature Genetics(2021)10.1038/s41588-020-00750-6

N/A

0.790DataRank · unranked

193 citations

Jessica Giordano, Anuj Srivastava, Min Jin Ha, Michael W. Lloyd, Roebi de Bruijn +57 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1265

N/A

0.727DataRank · unranked

126 citations

Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje +11 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

Artificial intelligence in clinical and translational science: Successes, challenges and opportunities

Clinical and Translational Science(2021)10.1111/cts.13175

N/A

0.593DataRank · unranked

51 citations

Paula K. Shireman, Funda Meric‐Bernstam, Meredith Zozus, Xiaoqian Jiang, Bradley B. Brimhall +9 more

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4048

N/A

0.510DataRank · unranked

29 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

npj Precision Oncology(2021)10.1038/s41698-021-00159-2

N/A

0.505DataRank · unranked

28 citations

David S. Hong, Siqing Fu, Daniel D. Karp, Sarina A. Piha‐Paul, Merrill S. Kies +16 more

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

Cancer(2023)10.1002/cncr.34820

N/A

0.488DataRank · unranked

9 citations

Janet Tu, Denái R. Milton, Bülent Yılmaz, Yanyan Tian, Frank V. Fossella +8 more

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0

N/A

0.470DataRank · unranked

22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0471

N/A

0.464DataRank · unranked

21 citations

Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis +29 more

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae314

N/A

0.443DataRank · unranked

10 citations

William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +19 more

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine(2024)10.1002/cam4.6877

N/A

0.418DataRank · unranked

8 citations

Bettzy Stephen, Siqing Fu, Daniel D. Karp, Vivek Subbiah, Jordi Rodon Ahnert +8 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0.416DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

ESMO Open(2021)10.1016/j.esmoop.2021.100079

N/A

0.396DataRank · unranked

13 citations

Ruth Sacks, Ishwaria M. Subbiah, Neele Drobnitzky, Sarina A. Piha‐Paul, David S. Hong +15 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0.373DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2024.12.019

N/A

0.343DataRank · unranked

7 citations

Bettzy Stephen, Muhammad Rizwan Khawaja, Yali Yang, Israa Salih, Elizve Barrientos-Toro +11 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0.312DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer

npj Precision Oncology(2024)10.1038/s41698-024-00729-0

N/A

0.298DataRank · unranked

5 citations

Li Zhao, Xingzhi Song, Xiaogang Wu, Savitri Krishnamurthy, Takashi Semba +63 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0.269DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study

ESMO Open(2023)10.1016/j.esmoop.2023.101609

N/A

0.256DataRank · unranked

3 citations

X. Wang, Najat C. Daw, C.E. Herzog, Ishwaria M. Subbiah, Wafik Zaky +10 more

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis

Cancer Research(2024)10.1158/0008-5472.can-23-1349

Top 62%

0.222DataRank

Top 62%3 citations

Xing Yi Woo, Soner Koc, Todd Sheridan, Steven B. Neuhauser, Shidan Wang +49 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0.208DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-10

N/A

0.165DataRank · unranked

2 citations

Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger +6 more

PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.15.464537

Top 72%

0.110DataRank

Top 72%1 citations

Michael W. Lloyd, Jeffrey Grover, Sara Seepo, Sai Lakshmi Subramanian, Manisha Ray +34 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Figshare(2023)10.1158/1078-0432.22446608.v1

Top 100%

0DataRank

Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733.v1

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743.v1

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

(2023)10.1158/1078-0432.c.6531065.v1

Top 100%

0DataRank

Top 100%0 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

Data from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

(2023)10.1158/1078-0432.c.6530036

Top 100%

0DataRank

Top 100%0 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2023)10.1158/1078-0432.22446608

Top 100%

0DataRank

Top 100%0 citations

Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins +10 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0584

N/A

0DataRank · unranked

0 citations

Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa +9 more

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

The Oncologist(2024)10.1093/oncolo/oyad338

N/A

0DataRank · unranked

27 citations

Binghe Xu, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam +20 more

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0838

N/A

0DataRank · unranked

25 citations

Kurt W. Evans, Bailiang Wang, Ming Zhao, Argun Akçakanat, Maria Gabriela Raso +14 more

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology(2024)10.1038/s41698-024-00563-4

N/A

0DataRank · unranked

25 citations

Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven I. Sherman +8 more

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1948

N/A

0DataRank · unranked

22 citations

Erkan Yuca, Kurt W. Evans, Ming Zhao, Takanori Maejima, Tsuyoshi Karibe +12 more

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-1763

N/A

0DataRank · unranked

13 citations

Virginia Giuliani, Wei‐Lien Wang, Daniel J. McGrail, Christopher A. Bristow, Natalie Y.L. Ngoi +46 more

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2819

N/A

0DataRank · unranked

12 citations

Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo +19 more

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types

JCO Precision Oncology(2024)10.1200/po-24-00419

N/A

0DataRank · unranked

2 citations

Michael Kahle, Sun‐Hee Kim, Arash Ronaghy, Richard K. Yang, Keyur P. Patel +7 more

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Molecular Cancer(2024)10.1186/s12943-024-01982-4

N/A

0DataRank · unranked

2 citations

Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell +9 more

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1233

N/A

0DataRank · unranked

1 citations

Kurt W. Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N. Kwong +16 more

Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.tps5626

N/A

0DataRank · unranked

9 citations

Hind Rafei, Rafet Başar, Pinaki P. Banerjee, Zeyad Metwalli, Kathryn Lito +13 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples

Nature Communications(2025)10.1038/s41467-025-63414-1

N/A

0DataRank · unranked

24 citations

Max Molina Ayala, Sharia Hernandez, Wei Lu, Khaja Khan, Alejandra G. Serrano +69 more

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer

npj Precision Oncology(2025)10.1038/s41698-025-01041-1

N/A

0DataRank · unranked

14 citations

Tuyen Bui, Juliana Navarro-Yepes, Sanaz Ghotbaldini, Bethanie Quintela, Catherine K. Luo +19 more

Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling

npj Breast Cancer(2025)10.1038/s41523-025-00868-y

N/A

0DataRank · unranked

9 citations

Joanne Xiu, Reshma Mahtani, Ana C. Sandoval Leon, Funda Meric‐Bernstam, Jennifer R. Ribeiro +8 more

FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

Journal of Clinical Investigation(2025)10.1172/jci173757

N/A

0DataRank · unranked

4 citations

Hirohito Yamaguchi, Yuan Gao, Weiya Xia, Jeffrey T. Chang, Yu‐Chun Hsiao +27 more

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

Cancer(2025)10.1002/cncr.35728

N/A

0DataRank · unranked

4 citations

Filip Janku, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Timothy A. Yap +8 more

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0884

N/A

0DataRank · unranked

1 citations

Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng +10 more

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy

RSC Medicinal Chemistry(2025)10.1039/d5md00245a

N/A

0DataRank · unranked

1 citations

Neetu Dayal, Kofi Baffour-Awuah Owusu, Mandeep Kaur Hunjan, Shriya Pandey, H. Harper +14 more

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial

UNC Libraries(2025)10.17615/dgtt-ap31

N/A

0DataRank · unranked

0 citations

Julie R. Gralow, Edith Perez, Kevin Kalinsky, Gabriel N. Hortobágyi, Nancy U. Lin +19 more

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

The Oncologist(2025)10.1093/oncolo/oyaf413

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Emily Thompson, R. Jason Stafford, Hung Le, Lei Kang +12 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.05.021

N/A

0DataRank · unranked

73 citations

Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson +17 more

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Oncotarget(2020)10.18632/oncotarget.27503

N/A

0DataRank · unranked

24 citations

Ming Zhao, Argun Akçakanat, Kurt W. Evans, Erkan Yuca, Ecaterina Ileana Dumbrava +3 more

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0037

N/A

0DataRank · unranked

30 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1963

N/A

0DataRank · unranked

369 citations

Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham +11 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230

N/A

0DataRank · unranked

41 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

Associations between the gut microbiome and fatigue in cancer patients

Scientific Reports(2021)10.1038/s41598-021-84783-9

N/A

0DataRank · unranked

45 citations

Tito R. Mendoza, Liangliang Zhang, Siqing Fu, Sarina A. Piha‐Paul, David S. Hong +10 more

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

ESMO Open(2021)10.1016/j.esmoop.2021.100357

N/A

0DataRank · unranked

26 citations

Jiří Polívka, Hong Huang, I. Treskova, Kristýna Pivovarčíková, T. Fikrle +7 more

Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

Blood Advances(2021)10.1182/bloodadvances.2021006156

N/A

0DataRank · unranked

8 citations

Ran Zhang, Chenghui Ren, Yi Xu, Shuhong Wu, Carrie Meng +19 more

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single cell DNA sequencing

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.11.16.468877

N/A

0DataRank · unranked

8 citations

Min Hu, Emi Sei, Funda Meric‐Bernstam, Nicholas E. Navin, Jake Leighton

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.19.464994

N/A

0DataRank · unranked

3 citations

Jing Wang, Bingliang Fang, Funda Meric‐Bernstam, Jack A. Roth, Min Jin Ha +1 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5565

N/A

0DataRank · unranked

0 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +15 more

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

Journal of Clinical Oncology(2022)10.1200/jco.21.02767

N/A

0DataRank · unranked

255 citations

Amber M. Johnson, Jeffrey Sklar, Neal I. Lindeman, Kathleen N. Moore, Shridar Ganesan +13 more

A path to translation: How 3D patient tumor avatars enable next generation precision oncology

Cancer Cell(2022)10.1016/j.ccell.2022.09.017

N/A

0DataRank · unranked

66 citations

Margarida Barroso, Milan G. Chheda, Hans Clevers, Élena Elez, Salma Kaochar +21 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts

Scientific Reports(2022)10.1038/s41598-022-16933-6

N/A

0DataRank · unranked

21 citations

Jing Wang, Bingliang Fang, Funda Meric‐Bernstam, Jack A. Roth, Min Jin Ha +1 more

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Scientific Reports(2022)10.1038/s41598-022-05193-z

N/A

0DataRank · unranked

9 citations

Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen +12 more

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2509

N/A

0DataRank · unranked

9 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.004

N/A

0DataRank · unranked

8 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +16 more

Natural History and Characteristics of ERBB2 -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-0885

N/A

0DataRank · unranked

3 citations

Sheau‐Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bédard +18 more

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts

Research Square(2022)10.21203/rs.3.rs-1464274/v1

N/A

0DataRank · unranked

0 citations

Jing Wang, Bingliang Fang, Funda Meric‐Bernstam, Jack A. Roth, Min Jin Ha +1 more

A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.26.512745

Top 100%

0DataRank

Top 100%0 citations

X. Woo, Soner Koc, Todd Sheridan, Steven B. Neuhauser, Shidan Wang +45 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Research Square(2022)10.21203/rs.3.rs-2248209/v1

N/A

0DataRank · unranked

0 citations

Turçin Saridogan, Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca +11 more

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers

Cancer Research(2023)10.1158/0008-5472.can-23-0705

N/A

0DataRank · unranked

53 citations

Nicole M. Kettner, Xiayu Rao, Cassandra Santaella Bishop, Tuyen Bui, Hannah F. Wingate +10 more

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0103

N/A

0DataRank · unranked

29 citations

Kurt W. Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q. Rizvi, Xiaofeng Zheng +11 more

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

npj Breast Cancer(2023)10.1038/s41523-023-00573-8

N/A

0DataRank · unranked

29 citations

Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans +8 more

Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

Annals of Surgical Oncology(2023)10.1245/s10434-022-12972-5

N/A

0DataRank · unranked

21 citations

Vera J. Suman, Hannah F. Wingate, A. Marilyn Leitch, Gary Unzeitig, Judy C. Boughey +4 more

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3629

N/A

0DataRank · unranked

21 citations

Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing +29 more

Discordance of HER2 Expression and/or Amplification on Repeat Testing

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0630

N/A

0DataRank · unranked

19 citations

Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant +5 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Scientific Reports(2023)10.1038/s41598-023-46586-y

N/A

0DataRank · unranked

15 citations

Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott +11 more

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Annals of Oncology(2023)10.1016/j.annonc.2023.07.002

N/A

0DataRank · unranked

7 citations

Mimi I. Hu, Maria E. Cabanillas, Jie Wu, Funda Meric‐Bernstam, Vivek Subbiah +1 more

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

Cancer(2023)10.1002/cncr.34773

N/A

0DataRank · unranked

5 citations

Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina A. Piha‐Paul, Julia Ann Moore +18 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Data from Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

(2023)10.1158/1078-0432.c.6528374.v1

N/A

0DataRank · unranked

0 citations

Amber M. Johnson, Ecaterina E. Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt +4 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Funda Meric‐Bernstam

Indexed papers

Top data-sharing exemplar

Papers